U.S. researchers find antibodies that can kill prostate cancer cells in mice, and can destroy the deadly disease even in an advanced stage. Although not yet reached the desired target, this research adds a new step of relief efforts for prostate cancer has claimed the world's population of 500 thousand people every year.
Antibodies, called F77, published in Research Report to the U.S. National Academy (PNAS). When injected in mice, F77 binds major networks where prostate cancer works, and encourage the performance of other networks to prevent tumor development by 85 percent. A similar study by the University of Pennsylvania to prove this, that androgen-independent cells arise when incurable prostate cancer.
However, F77 does not work on normal tissue or tumors in other parts of the body, such as colon, kidney, cervix, pancreas, lungs, skin, and bladder. Antibodies produced by the new F77 can work to overcome androgen-independent prostate cancer that spread in the bone so it is difficult to treat.
In the past five years, the number of prostate cancer recovery only reached 34 percent. World Health Organization (WHO) noted that 500 thousand people worldwide become victims of this cancer malignancy each year.
0 comments:
Post a Comment